Cargando…
The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3-methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent m...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956650/ https://www.ncbi.nlm.nih.gov/pubmed/20976142 http://dx.doi.org/10.1371/journal.pone.0013452 |
_version_ | 1782188168149204992 |
---|---|
author | Sotnikova, Tatyana D. Beaulieu, Jean-Martin Espinoza, Stefano Masri, Bernard Zhang, Xiaodong Salahpour, Ali Barak, Larry S. Caron, Marc G. Gainetdinov, Raul R. |
author_facet | Sotnikova, Tatyana D. Beaulieu, Jean-Martin Espinoza, Stefano Masri, Bernard Zhang, Xiaodong Salahpour, Ali Barak, Larry S. Caron, Marc G. Gainetdinov, Raul R. |
author_sort | Sotnikova, Tatyana D. |
collection | PubMed |
description | Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3-methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent manner and these effects are partially mediated by the trace amine associated receptor 1 (TAAR1). Unbiased in vivo screening of putative trace amine receptor ligands for potential effects on the movement control revealed that 3-MT infused in the brain is able to induce a complex set of abnormal involuntary movements in mice acutely depleted of dopamine. In normal mice, the central administration of 3-MT caused a temporary mild hyperactivity with a concomitant set of abnormal movements. Furthermore, 3-MT induced significant ERK and CREB phosphorylation in the mouse striatum, signaling events generally related to PKA-mediated cAMP accumulation. In mice lacking TAAR1, both behavioral and signaling effects of 3-MT were partially attenuated, consistent with the ability of 3-MT to activate TAAR1 receptors and cause cAMP accumulation as well as ERK and CREB phosphorylation in cellular assays. Thus, 3-MT is not just an inactive metabolite of DA, but a novel neuromodulator that in certain situations may be involved in movement control. Further characterization of the physiological functions mediated by 3-MT may advance understanding of the pathophysiology and pharmacology of brain disorders involving abnormal dopaminergic transmission, such as Parkinson's disease, dyskinesia and schizophrenia. |
format | Text |
id | pubmed-2956650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-29566502010-10-25 The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator Sotnikova, Tatyana D. Beaulieu, Jean-Martin Espinoza, Stefano Masri, Bernard Zhang, Xiaodong Salahpour, Ali Barak, Larry S. Caron, Marc G. Gainetdinov, Raul R. PLoS One Research Article Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3-methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent manner and these effects are partially mediated by the trace amine associated receptor 1 (TAAR1). Unbiased in vivo screening of putative trace amine receptor ligands for potential effects on the movement control revealed that 3-MT infused in the brain is able to induce a complex set of abnormal involuntary movements in mice acutely depleted of dopamine. In normal mice, the central administration of 3-MT caused a temporary mild hyperactivity with a concomitant set of abnormal movements. Furthermore, 3-MT induced significant ERK and CREB phosphorylation in the mouse striatum, signaling events generally related to PKA-mediated cAMP accumulation. In mice lacking TAAR1, both behavioral and signaling effects of 3-MT were partially attenuated, consistent with the ability of 3-MT to activate TAAR1 receptors and cause cAMP accumulation as well as ERK and CREB phosphorylation in cellular assays. Thus, 3-MT is not just an inactive metabolite of DA, but a novel neuromodulator that in certain situations may be involved in movement control. Further characterization of the physiological functions mediated by 3-MT may advance understanding of the pathophysiology and pharmacology of brain disorders involving abnormal dopaminergic transmission, such as Parkinson's disease, dyskinesia and schizophrenia. Public Library of Science 2010-10-18 /pmc/articles/PMC2956650/ /pubmed/20976142 http://dx.doi.org/10.1371/journal.pone.0013452 Text en Sotnikova et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Sotnikova, Tatyana D. Beaulieu, Jean-Martin Espinoza, Stefano Masri, Bernard Zhang, Xiaodong Salahpour, Ali Barak, Larry S. Caron, Marc G. Gainetdinov, Raul R. The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator |
title | The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator |
title_full | The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator |
title_fullStr | The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator |
title_full_unstemmed | The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator |
title_short | The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator |
title_sort | dopamine metabolite 3-methoxytyramine is a neuromodulator |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956650/ https://www.ncbi.nlm.nih.gov/pubmed/20976142 http://dx.doi.org/10.1371/journal.pone.0013452 |
work_keys_str_mv | AT sotnikovatatyanad thedopaminemetabolite3methoxytyramineisaneuromodulator AT beaulieujeanmartin thedopaminemetabolite3methoxytyramineisaneuromodulator AT espinozastefano thedopaminemetabolite3methoxytyramineisaneuromodulator AT masribernard thedopaminemetabolite3methoxytyramineisaneuromodulator AT zhangxiaodong thedopaminemetabolite3methoxytyramineisaneuromodulator AT salahpourali thedopaminemetabolite3methoxytyramineisaneuromodulator AT baraklarrys thedopaminemetabolite3methoxytyramineisaneuromodulator AT caronmarcg thedopaminemetabolite3methoxytyramineisaneuromodulator AT gainetdinovraulr thedopaminemetabolite3methoxytyramineisaneuromodulator AT sotnikovatatyanad dopaminemetabolite3methoxytyramineisaneuromodulator AT beaulieujeanmartin dopaminemetabolite3methoxytyramineisaneuromodulator AT espinozastefano dopaminemetabolite3methoxytyramineisaneuromodulator AT masribernard dopaminemetabolite3methoxytyramineisaneuromodulator AT zhangxiaodong dopaminemetabolite3methoxytyramineisaneuromodulator AT salahpourali dopaminemetabolite3methoxytyramineisaneuromodulator AT baraklarrys dopaminemetabolite3methoxytyramineisaneuromodulator AT caronmarcg dopaminemetabolite3methoxytyramineisaneuromodulator AT gainetdinovraulr dopaminemetabolite3methoxytyramineisaneuromodulator |